Biomea Fusion's COVALENT-111 study shows icovamenib reduces HbA1c significantly in T2D patients, with no safety concerns or ...

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the ...

Biomea also drilled down into subgroups of patients with mild age-related diabetes and severe insulin-deficient diabetes, ...

Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.

And it’s also on sale right now, so that’s a win for you as well. See at Amazon Currently priced at $100, down from its ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

Crinecerfont is the first new treatment in 70 years for classic CAH and the only one that directly reduces excess ...

Affiliate content. Discover the 14 best colostrum supplements, offering exceptional options to support immunity, gut health, ...

The latest data from a new CDC report show a 700% plus increase in overdose deaths involving the fentanyl analog carfentanil ...

Diabetes, a chronic condition impacting millions globally, often brings along complications like insulin resistance and fatty ...

Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the ...

Ajna BioSciences and British American Tobacco, yielded positive results from a phase-1 dose trial of AJA001, its cannabis-based drug candidate to treat symptoms of autism spectrum disorder ・Results ...